Table 2.
In vitro activity of posaconazole and other antifungal agents against clinical strains of moulds and yeasts [5]
| MIC90 values (µg ml−1) | |||
|---|---|---|---|
| Organism | POS | ITC | VRC |
| Aspergillus spp. | |||
| A. fumigatus | 0.5 | 1.0 | 0.5 |
| A. niger | 0.5 | 2.0 | 2.0 |
| A. flavus | 0.5 | 1.0 | 1.0 |
| A. terreus | 0.25 | 0.5 | 0.5 |
| Zygomycetes | |||
| Rhizopus spp. | 8.0 | 32.0 | 128.0 |
| Mucor spp. | 16.0 | 32.0 | 128.0 |
| Absidia spp. | 0.25 | 0.5 | 128.0 |
| Candida spp. | |||
| C. albicans | 0.063 | 0.25 | 0.063 |
| C. glabrata | 2.0 | 4.0 | 2.0 |
| C. parapsilosis | 0.25 | 0.5 | 0.125 |
| C. tropicalis | 0.25 | 0.5 | 0.5 |
| C. krusei | 1.0 | 1.0 | 0.5 |
| C. dubliniensis | 0.125 | 0.5 | 0.125 |
| Other organisms | |||
| Cryptococcus spp. | 0.25 | 0.5 | 0.125 |
| Fusarium oxysporum | 4.0 | ND | 16.0 |
| F. solani | 32.0 | ND | 32.0 |
ITC, itraconazole; MIC90, minimal inhibitory concentration at which the growth of 90% of isolates are inhibited; ND, not determined; POS, posaconazole; VRC, voriconazole. Table adapted from Keating GM. Posaconazole. Drugs 2005; 65: 1553–67, with permission [5].